Faslodex First-Line Study Suggests Potential Inferiority To Tamoxifen – FDA
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Results of a trial assessing first-line use of AstraZeneca’s Faslodex in advanced breast cancer suggest that the agent "may not be equally efficacious as tamoxifen in the first-line setting," FDA said in review documents.